Anorexigenic Effects of GLP-1 and Its Analogues (Q37976358)

26 August 2017

title

Anorexigenic effects of GLP-1 and its analogues (English)

1 reference

26 August 2017

Anorexigenic Effects of GLP-1 and Its Analogues (English)

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

22 December 2024

author name string

Baptist Gallwitz

1

1 reference

26 August 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=22249815

22 December 2024

publication date

1 January 2012

1 reference

26 August 2017

2012

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=22249815

full work available at URL

22 December 2024

https://link.springer.com/content/pdf/10.1007/978-3-642-24716-3_8

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

Handbook of experimental pharmacology

22 December 2024

published in

1 reference

26 August 2017

issue

209

1 reference

26 August 2017

page(s)

185-207

1 reference

Glucagon-like peptide 1 stimulates hypothalamic proopiomelanocortin neurons

26 August 2017

cites work

1 reference

3 January 2024

https://opencitations.net/index/api/v1/citations/10.1523/JNEUROSCI.1025-07.2007

The inhibitory effects of peripheral administration of peptide YY(3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway

1

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

Clinical review: The extrapancreatic effects of glucagon-like peptide-1 and related peptides

22 December 2024

2

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

GLP-1 and extra-islet effects

22 December 2024

3

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study

22 December 2024

4

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

Biology of incretins: GLP-1 and GIP

22 December 2024

5

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis.

22 December 2024

6

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose homeostasis

22 December 2024

7

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

Gut hormone PYY(3-36) physiologically inhibits food intake

22 December 2024

8

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

Inhibition of food intake in obese subjects by peptide YY3-36

22 December 2024

9

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

Glucagon-like peptide-1 (GLP-1) releases thyrotropin (TSH): characterization of binding sites for GLP-1 on alpha-TSH cells

22 December 2024

10

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

Glucagon-like peptide-1 stimulates luteinizing hormone-releasing hormone secretion in a rodent hypothalamic neuronal cell line

22 December 2024

11

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

Exon duplication and divergence in the human preproglucagon gene

22 December 2024

12

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

22 December 2024

13

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

PYY3-36 as an anti-obesity drug target.

22 December 2024

14

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

Minireview: Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system

22 December 2024

15

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

Intracerebroventricular injection of fusaric acid attenuates the anorexia by glucagon-like peptide-1 in the neonatal chick

22 December 2024

17

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks

22 December 2024

18

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

Lixisenatide for type 2 diabetes mellitus

22 December 2024

19

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

Pharmaceutical strategies utilizing recombinant human serum albumin

22 December 2024

20

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes

22 December 2024

21

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

The incretin concept today

22 December 2024

22

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

Role of the bypassed proximal intestine in the anti-diabetic effects of bariatric surgery

22 December 2024

23

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

Intestinal hormones and regulation of satiety: the case for CCK, GLP-1, PYY, and Apo A-IV.

22 December 2024

25

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons

22 December 2024

26

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

Peripheral oxyntomodulin reduces food intake and body weight gain in rats.

22 December 2024

27

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

Effect of GLP-1 on gastric volume, emptying, maximum volume ingested, and postprandial symptoms in humans

22 December 2024

28

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial

22 December 2024

29

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

Postprandial diabetic glucose tolerance is normalized by gastric bypass feeding as opposed to gastric feeding and is associated with exaggerated GLP-1 secretion: a case report

22 December 2024

30

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

The biology of incretin hormones

22 December 2024

31

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

22 December 2024

32

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

22 December 2024

33

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

Taste cells of the gut and gastrointestinal chemosensation

22 December 2024

34

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

Feedback inhibition of insulin secretion by insulin: relation to the hyperinsulinemia of obesity

22 December 2024

35

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

Insulinotropic hormone glucagon-like peptide-I(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells

22 December 2024

36

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans

22 December 2024

37

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity

22 December 2024

38

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

The central corticotropin-releasing factor and glucagon-like peptide-1 in food intake of the neonatal chick

22 December 2024

39

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

22 December 2024

40

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes

22 December 2024

41

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein

22 December 2024

42

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites

22 December 2024

44

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

Stimulation of cloned human glucagon-like peptide 1 receptor expressed in HEK 293 cells induces cAMP-dependent activation of calcium-induced calcium release

22 December 2024

45

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

American Journal of Physiology

22 December 2024

46

276

R1541

JP Gutzwiller

1999

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

The Physiology of Glucagon-like Peptide 1

22 December 2024

47

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

Glucagon-like peptide-1, glucose homeostasis and diabetes

22 December 2024

48

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

Gut-expressed gustducin and taste receptors regulate secretion of glucagon-like peptide-1

22 December 2024

50

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

Distribution of glucagonlike peptide I (GLP-I), glucagon, and glicentin in the rat brain: an immunocytochemical study

22 December 2024

51

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

Glucagon-like peptide-1 evokes action potentials and increases cytosolic Ca2 in rat nodose ganglion neurons

22 December 2024

52

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

Acute effects of gastric bypass versus gastric restrictive surgery on beta-cell function and insulinotropic hormones in severely obese patients with type 2 diabetes

22 December 2024

53

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes

22 December 2024

54

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

The diverse roles of specific GLP-1 receptors in the control of food intake and the response to visceral illness

22 December 2024

55

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years

22 December 2024

56

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem

22 December 2024

57

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

Central Administration of Glucagon-Like Peptide-1 Activates Hypothalamic Neuroendocrine Neurons in the Rat*

22 December 2024

58

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

Glucagon-like peptide 1 receptor signaling influences topography of islet cells in mice

22 December 2024

59

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes

22 December 2024

60

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)--preclinical and clinical results

22 December 2024

62

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future.

22 December 2024

63

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

Glucagon-like peptide 1 as a regulator of food intake and body weight: therapeutic perspectives

22 December 2024

65

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes

22 December 2024

66

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

Absence of a memory effect for the insulinotropic action of glucagon-like peptide 1 (GLP-1) in healthy volunteers

22 December 2024

67

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects

22 December 2024

68

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

Effects of 3 Months of Continuous Subcutaneous Administration of Glucagon-Like Peptide 1 in Elderly Patients With Type 2 Diabetes

22 December 2024

69

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

Effect of GLP-1 (glucagon-like peptide 1:7-36 amide) on porcine pancreatic endocrine cell proliferation and insulin secretion

22 December 2024

70

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

Central glucagon like peptide-1 delays solid gastric emptying via central CRF and peripheral sympathetic pathway in rats

22 December 2024

71

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men

22 December 2024

72

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

Prandial subcutaneous injections of glucagon-like peptide-1 cause weight loss in obese human subjects.

22 December 2024

73

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

Reduced incretin effect in type 2 (non-insulin-dependent) diabetes

22 December 2024

74

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients

22 December 2024

75

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

How the hindgut can cure type 2 diabetes. Ileal transposition improves glucose metabolism and beta-cell function in Goto-kakizaki rats through an enhanced Proglucagon gene expression and L-cell number

22 December 2024

79

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

Oxyntomodulin and glicentin are potent inhibitors of the fed motility pattern in small intestine

22 December 2024

80

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

Improvement in glucose metabolism after bariatric surgery: comparison of laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy: a prospective randomized trial.

22 December 2024

81

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

Meat hydrolysate and essential amino acid-induced glucagon-like peptide-1 secretion, in the human NCI-H716 enteroendocrine cell line, is regulated by extracellular signal-regulated kinase1/2 and p38 mitogen-activated protein kinases

22 December 2024

84

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing

22 December 2024

85

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism

22 December 2024

86

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

Regulation of islet hormone release and gastric emptying by endogenous glucagon-like peptide 1 after glucose ingestion

22 December 2024

87

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

Gastric emptying and release of incretin hormones after glucose ingestion in humans

22 December 2024

88

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans

22 December 2024

90

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

Metabolic effects of the incretin mimetic exenatide in the treatment of type 2 diabetes

22 December 2024

92

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

Central nervous system control of food intake

22 December 2024

93

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

The role of CNS glucagon-like peptide-1 (7-36) amide receptors in mediating the visceral illness effects of lithium chloride.

22 December 2024

94

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

Acute effects of glucagon-like peptide-1 on hypothalamic neuropeptide and AMP activated kinase expression in fasted rats

22 December 2024

95

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

Modulation of taste sensitivity by GLP-1 signaling

22 December 2024

96

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

Interrelationship among insulin, glucagon and somatostatin secretory responses to exendin-4 in the perfused rat pancreas

22 December 2024

98

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure

22 December 2024

99

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

Albiglutide: a new GLP-1 analog for the treatment of type 2 diabetes

22 December 2024

100

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

Glucagon-like peptide 1(7-36) amide's central inhibition of feeding and peripheral inhibition of drinking are abolished by neonatal monosodium glutamate treatment

22 December 2024

103

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

Bariatric surgery and the gut hormone response

22 December 2024

105

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

Physiology: does gut hormone PYY3-36 decrease food intake in rodents?

22 December 2024

106

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

A role for glucagon-like peptide-1 in the central regulation of feeding

22 December 2024

107

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes

22 December 2024

109

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

Narrative review: effect of bariatric surgery on type 2 diabetes mellitus

22 December 2024

111

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

Gastric distension induces c-Fos in medullary GLP-1/2-containing neurons

22 December 2024

112

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

Gastric distention activates satiety circuitry in the human brain

22 December 2024

113

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

Molecular pharmacology of promiscuous seven transmembrane receptors sensing organic nutrients.

22 December 2024

115

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7-36 amide on gastric acid secretion in humans depends on an intact vagal innervation

22 December 2024

116

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta).

22 December 2024

117

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study

22 December 2024

118

1 reference

https://api.crossref.org/works/10.1007/978-3-642-24716-3_8

22 December 2024

Identifiers

1 reference

26 August 2017

1 reference